A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression

Matthew S. Stanford, Rebecca J. Houston, Charles W Mathias, Kevin W. Greve, Nicole R. Villemarette-Pittman, Donald Adams

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The present study examines the behavioral and psychophysiological effects of phenytoin (PHT) in individuals who display impulsive-aggressive outbursts. In a double-blind placebo-controlled crossover design, individuals meeting previously established criteria for impulsive aggression were administered PHT and placebo during separate 6-week conditions. The efficacy measures used were the Overt Aggression Scale (OAS) and the Profile of Mood States (POMS). Psychophysiological measures (evoked potentials) were taken at baseline and at the end of each 6-week condition. Photic stimulation was used to evoke the mid-latency P1-N1-P2 waveform complex. Analysis indicated a significant decrease in the frequency of impulsive-aggressive outbursts during PHT administration compared to baseline and placebo. Analysis of the psychophysiological data showed significantly increased P1 amplitude and significantly longer N1 latency during PHT administration. In addition, a reduction in N1 amplitude during PHT administration was also suggested. These findings indicate reparation of physiological abnormalities previously observed in impulsive-aggressive individuals and imply more efficient sensory processing and effective orienting of attention. Taken together, these results provide insight as to the physiological mechanisms by which PHT serves to ameliorate impulsive-aggressive behavior.

Original languageEnglish (US)
Pages (from-to)193-203
Number of pages11
JournalPsychiatry Research
Volume103
Issue number2-3
DOIs
StatePublished - Sep 20 2001
Externally publishedYes

Fingerprint

Phenytoin
Aggression
Cross-Over Studies
Placebos
Photic Stimulation
Impulsive Behavior
Evoked Potentials

Keywords

  • Aggression
  • Evoked potentials
  • N1
  • P1
  • Phenytoin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. / Stanford, Matthew S.; Houston, Rebecca J.; Mathias, Charles W; Greve, Kevin W.; Villemarette-Pittman, Nicole R.; Adams, Donald.

In: Psychiatry Research, Vol. 103, No. 2-3, 20.09.2001, p. 193-203.

Research output: Contribution to journalArticle

Stanford, Matthew S. ; Houston, Rebecca J. ; Mathias, Charles W ; Greve, Kevin W. ; Villemarette-Pittman, Nicole R. ; Adams, Donald. / A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. In: Psychiatry Research. 2001 ; Vol. 103, No. 2-3. pp. 193-203.
@article{a09ebd0a0b074200940383fb0a95938b,
title = "A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression",
abstract = "The present study examines the behavioral and psychophysiological effects of phenytoin (PHT) in individuals who display impulsive-aggressive outbursts. In a double-blind placebo-controlled crossover design, individuals meeting previously established criteria for impulsive aggression were administered PHT and placebo during separate 6-week conditions. The efficacy measures used were the Overt Aggression Scale (OAS) and the Profile of Mood States (POMS). Psychophysiological measures (evoked potentials) were taken at baseline and at the end of each 6-week condition. Photic stimulation was used to evoke the mid-latency P1-N1-P2 waveform complex. Analysis indicated a significant decrease in the frequency of impulsive-aggressive outbursts during PHT administration compared to baseline and placebo. Analysis of the psychophysiological data showed significantly increased P1 amplitude and significantly longer N1 latency during PHT administration. In addition, a reduction in N1 amplitude during PHT administration was also suggested. These findings indicate reparation of physiological abnormalities previously observed in impulsive-aggressive individuals and imply more efficient sensory processing and effective orienting of attention. Taken together, these results provide insight as to the physiological mechanisms by which PHT serves to ameliorate impulsive-aggressive behavior.",
keywords = "Aggression, Evoked potentials, N1, P1, Phenytoin",
author = "Stanford, {Matthew S.} and Houston, {Rebecca J.} and Mathias, {Charles W} and Greve, {Kevin W.} and Villemarette-Pittman, {Nicole R.} and Donald Adams",
year = "2001",
month = "9",
day = "20",
doi = "10.1016/S0165-1781(01)00287-6",
language = "English (US)",
volume = "103",
pages = "193--203",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression

AU - Stanford, Matthew S.

AU - Houston, Rebecca J.

AU - Mathias, Charles W

AU - Greve, Kevin W.

AU - Villemarette-Pittman, Nicole R.

AU - Adams, Donald

PY - 2001/9/20

Y1 - 2001/9/20

N2 - The present study examines the behavioral and psychophysiological effects of phenytoin (PHT) in individuals who display impulsive-aggressive outbursts. In a double-blind placebo-controlled crossover design, individuals meeting previously established criteria for impulsive aggression were administered PHT and placebo during separate 6-week conditions. The efficacy measures used were the Overt Aggression Scale (OAS) and the Profile of Mood States (POMS). Psychophysiological measures (evoked potentials) were taken at baseline and at the end of each 6-week condition. Photic stimulation was used to evoke the mid-latency P1-N1-P2 waveform complex. Analysis indicated a significant decrease in the frequency of impulsive-aggressive outbursts during PHT administration compared to baseline and placebo. Analysis of the psychophysiological data showed significantly increased P1 amplitude and significantly longer N1 latency during PHT administration. In addition, a reduction in N1 amplitude during PHT administration was also suggested. These findings indicate reparation of physiological abnormalities previously observed in impulsive-aggressive individuals and imply more efficient sensory processing and effective orienting of attention. Taken together, these results provide insight as to the physiological mechanisms by which PHT serves to ameliorate impulsive-aggressive behavior.

AB - The present study examines the behavioral and psychophysiological effects of phenytoin (PHT) in individuals who display impulsive-aggressive outbursts. In a double-blind placebo-controlled crossover design, individuals meeting previously established criteria for impulsive aggression were administered PHT and placebo during separate 6-week conditions. The efficacy measures used were the Overt Aggression Scale (OAS) and the Profile of Mood States (POMS). Psychophysiological measures (evoked potentials) were taken at baseline and at the end of each 6-week condition. Photic stimulation was used to evoke the mid-latency P1-N1-P2 waveform complex. Analysis indicated a significant decrease in the frequency of impulsive-aggressive outbursts during PHT administration compared to baseline and placebo. Analysis of the psychophysiological data showed significantly increased P1 amplitude and significantly longer N1 latency during PHT administration. In addition, a reduction in N1 amplitude during PHT administration was also suggested. These findings indicate reparation of physiological abnormalities previously observed in impulsive-aggressive individuals and imply more efficient sensory processing and effective orienting of attention. Taken together, these results provide insight as to the physiological mechanisms by which PHT serves to ameliorate impulsive-aggressive behavior.

KW - Aggression

KW - Evoked potentials

KW - N1

KW - P1

KW - Phenytoin

UR - http://www.scopus.com/inward/record.url?scp=0035922122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035922122&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(01)00287-6

DO - 10.1016/S0165-1781(01)00287-6

M3 - Article

C2 - 11549407

AN - SCOPUS:0035922122

VL - 103

SP - 193

EP - 203

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2-3

ER -